Cargando…
Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
To affirm the short-term safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among people with multiple sclerosis (pwMS), 517 vaccinated and 174 unvaccinated pwMS were interviewed. 16.2% of the vaccinated pwMS reported at least one neurological symptom in their respective vaccine-related at-risk p...
Autores principales: | Etemadifar, Masoud, Abhari, Amir Parsa, Nouri, Hosein, Sigari, Amirhossein Akhavan, Piran Daliyeh, Seyed Mohammad, Maracy, Mohammad Reza, Salari, Mehri, Maleki, Shiva, Sedaghat, Nahad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009900/ https://www.ncbi.nlm.nih.gov/pubmed/35201963 http://dx.doi.org/10.1080/21645515.2022.2041945 |
Ejemplares similares
-
Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023) -
Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse
por: Etemadifar, Masoud, et al.
Publicado: (2022) -
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2022) -
Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
por: Sedaghat, Nahad, et al.
Publicado: (2023) -
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)